Reshaping Rheumatology – The era of biosimilars

In this CPD-accredited report, Professor Peter Nash of Griffith University, Australia, discusses perceptions and misconceptions with regard to biosimilars as therapy for rheumatological disease

You will learn:
Biosimilars are highly similar to the reference biologic
There is substantial evidence showing no inferiority between originator biologics and biosimilars in terms of efficacy and safety
A single or double switch between originators and biosimilars is safe
Indication extrapolation is permissible only when certain criteria have been met
Immunogenicity to the reference biologic will cross-react with the biosimilar.


ATTENTIONKindly note that if you attended the live webinar, you have already received 1 CPD point and will not be permitted to receive additional points for the report. Should this occur, the HPCSA will only record the 1 CPD point from the live webinar, invalidating any additional CPD points from the report. Please note deNovo Medica ensures uploading of your CPD points to the HPCSA: please don’t upload these yourself.

To access this module, please register or login: